Dose Finding Study of Subcutaneous Pertuzumab

[Billie]

Hi all, I have the opportunity to participate in this trial. A phase 1 open label, two-part, multicentre Perjeta subcutaneous dose-funding study but wanted to ask the groups opinion on whether it is a good idea to do so. I was diagnosed Her2, epositive in 2013 and completed treatment in 2014. Since then all has been clear. Do you think there is any harm in completing this trial or would it be better to "leave well alone". Really appreciate your thoughts.

Billie. NZ